* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's PEG Ratio or its related term are showing as below:
MEX:LABB'
s PEG Ratio Range Over the Past 10 Years
Min: 0.81 Med: 1.4 Max: 2.68
Current: 1.02
During the past 13 years, Genomma Lab InternacionalB de CV's highest PEG Ratio was 2.68. The lowest was 0.81. And the median was 1.40.
MEX:LABB's PEG Ratio is ranked better than 67.15% of 347
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs MEX:LABB: 1.02
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Genomma Lab InternacionalB de CV (MEX:LABB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Genomma Lab InternacionalB de CV PEG Ratio Related Terms
Genomma Lab InternacionalB de CV PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Genomma Lab InternacionalB de CV (MEX:LABB) has a PEG Ratio of 1.02 as of Jun. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 27% below median its historical median of 1.40. Over the past decade, Genomma Lab InternacionalB de CV's PEG Ratio has ranged from 0.81 to 2.68. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #114 out of 347 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is Genomma Lab InternacionalB de CV's PEG Ratio too high?
Genomma Lab InternacionalB de CV's current PEG Ratio of 1.02 is 27% below median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 2.68. The Drug Manufacturers industry median PEG Ratio is 1.71. Genomma Lab InternacionalB de CV's value of 1.02 is 40.4% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #114 out of 347 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #114 out of 347 companies for PEG Ratio. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median PEG Ratio is 1.71. Genomma Lab InternacionalB de CV's value of 1.02 is 40.4% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own PEG Ratio has ranged from 0.81 to 2.68 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.71, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current PEG Ratio of 1.02 is 40.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current PEG Ratio is 1.02, which is 27% below median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current PEG Ratio is 1.02, which is 27% below median its 10-year median of 1.40 and 40.4% below the Drug Manufacturers industry median of 1.71. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current PEG Ratio is 1.02 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
PEG Ratio: 1.02 (27% below median its 10-year median of 1.40)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 40.4% below the Drug Manufacturers median (#114 of 347)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
